364 related articles for article (PubMed ID: 32860031)
1. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia.
Gaudet D; Karwatowska-Prokopczuk E; Baum SJ; Hurh E; Kingsbury J; Bartlett VJ; Figueroa AL; Piscitelli P; Singleton W; Witztum JL; Geary RS; Tsimikas S; O'Dea LSL;
Eur Heart J; 2020 Oct; 41(40):3936-3945. PubMed ID: 32860031
[TBL] [Abstract][Full Text] [Related]
2. Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70.
Bergmark BA; Marston NA; Bramson CR; Curto M; Ramos V; Jevne A; Kuder JF; Park JG; Murphy SA; Verma S; Wojakowski W; Terra SG; Sabatine MS; Wiviott SD;
Circulation; 2022 May; 145(18):1377-1386. PubMed ID: 35369705
[TBL] [Abstract][Full Text] [Related]
3. Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study.
Foss-Freitas MC; Akinci B; Neidert A; Bartlett VJ; Hurh E; Karwatowska-Prokopczuk E; Oral EA
Lipids Health Dis; 2021 Dec; 20(1):174. PubMed ID: 34865644
[TBL] [Abstract][Full Text] [Related]
4. N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels.
Alexander VJ; Xia S; Hurh E; Hughes SG; O'Dea L; Geary RS; Witztum JL; Tsimikas S
Eur Heart J; 2019 Sep; 40(33):2785-2796. PubMed ID: 31329855
[TBL] [Abstract][Full Text] [Related]
5. Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: an analysis from the TRANSLATE-TIMI 70 trial.
Zimerman A; Wiviott SD; Park JG; Murphy SA; Ran X; Bramson CR; Curto M; Ramos V; Jevne A; Kuder JF; Verma S; Wojakowski W; Terra SG; Sabatine MS; Bergmark BA; Marston NA
Eur J Prev Cardiol; 2024 Mar; ():. PubMed ID: 38484368
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk.
Tardif JC; Karwatowska-Prokopczuk E; Amour ES; Ballantyne CM; Shapiro MD; Moriarty PM; Baum SJ; Hurh E; Bartlett VJ; Kingsbury J; Figueroa AL; Alexander VJ; Tami J; Witztum JL; Geary RS; O'Dea LSL; Tsimikas S; Gaudet D
Eur Heart J; 2022 Apr; 43(14):1401-1412. PubMed ID: 35025993
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.
Graham MJ; Lee RG; Brandt TA; Tai LJ; Fu W; Peralta R; Yu R; Hurh E; Paz E; McEvoy BW; Baker BF; Pham NC; Digenio A; Hughes SG; Geary RS; Witztum JL; Crooke RM; Tsimikas S
N Engl J Med; 2017 Jul; 377(3):222-232. PubMed ID: 28538111
[TBL] [Abstract][Full Text] [Related]
8. ANGPTL3 Deficiency and Risk of Hepatic Steatosis.
D'Erasmo L; Di Martino M; Neufeld T; Fraum TJ; Kang CJ; Burks KH; Di Costanzo A; Minicocci I; Bini S; Maranghi M; Pigna G; Labbadia G; Zheng J; Fierro D; Montali A; Ceci F; Catalano C; Davidson NO; Lucisano G; Nicolucci A; Arca M; Stitziel NO
Circulation; 2023 Nov; 148(19):1479-1489. PubMed ID: 37712257
[TBL] [Abstract][Full Text] [Related]
9. Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3.
Zimerman A; Wiviott SD; Park JG; Murphy SA; Ran X; Bramson CR; Curto M; Ramos V; Jevne A; Kuder JF; Verma S; Wojakowski W; Terra SG; Sabatine MS; Bergmark BA; Marston NA
J Clin Lipidol; 2024; 18(2):e261-e268. PubMed ID: 38158248
[TBL] [Abstract][Full Text] [Related]
10. Angiopoietin-like 3: An important protein in regulating lipoprotein levels.
Burks KH; Basu D; Goldberg IJ; Stitziel NO
Best Pract Res Clin Endocrinol Metab; 2023 May; 37(3):101688. PubMed ID: 35999139
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia.
Ahmad Z; Banerjee P; Hamon S; Chan KC; Bouzelmat A; Sasiela WJ; Pordy R; Mellis S; Dansky H; Gipe DA; Dunbar RL
Circulation; 2019 Aug; 140(6):470-486. PubMed ID: 31242752
[TBL] [Abstract][Full Text] [Related]
12. Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study.
Hussain A; Sun C; Selvin E; Nambi V; Coresh J; Jia X; Ballantyne CM; Hoogeveen RC
Eur J Prev Cardiol; 2022 Mar; 29(2):e53-e64. PubMed ID: 33580780
[TBL] [Abstract][Full Text] [Related]
13. A multi-purpose Japanese phase I study in the global development of vupanorsen: Randomized, placebo-controlled, single-ascending dose study in adults.
Fukuhara K; Furihata K; Matsuoka N; Itamura R; Ramos V; Hagi T; Kalluru H; Bramson C; Terra SG; Liu J
Clin Transl Sci; 2023 May; 16(5):886-897. PubMed ID: 37002654
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia.
Ruscica M; Zimetti F; Adorni MP; Sirtori CR; Lupo MG; Ferri N
Pharmacol Res; 2020 Mar; 153():104653. PubMed ID: 31931117
[TBL] [Abstract][Full Text] [Related]
15. The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?
Reeskamp LF; Tromp TR; Stroes ESG
Curr Opin Lipidol; 2020 Jun; 31(3):140-146. PubMed ID: 32324598
[TBL] [Abstract][Full Text] [Related]
16. Relationship between Serum Angiopoietin-like Proteins 3 and 8 and Atherogenic Lipid Biomarkers in Non-Diabetic Adults Depends on Gender and Obesity.
Murawska K; Krintus M; Kuligowska-Prusinska M; Szternel L; Stefanska A; Sypniewska G
Nutrients; 2021 Nov; 13(12):. PubMed ID: 34959891
[TBL] [Abstract][Full Text] [Related]
17. ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.
Akoumianakis I; Zvintzou E; Kypreos K; Filippatos TD
Curr Atheroscler Rep; 2021 Mar; 23(5):20. PubMed ID: 33694000
[TBL] [Abstract][Full Text] [Related]
18. Metabolomic Signature of Angiopoietin-Like Protein 3 Deficiency in Fasting and Postprandial State.
Tikkanen E; Minicocci I; Hällfors J; Di Costanzo A; D'Erasmo L; Poggiogalle E; Donini LM; Würtz P; Jauhiainen M; Olkkonen VM; Arca M
Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):665-674. PubMed ID: 30816800
[TBL] [Abstract][Full Text] [Related]
19. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol.
Xu YX; Redon V; Yu H; Querbes W; Pirruccello J; Liebow A; Deik A; Trindade K; Wang X; Musunuru K; Clish CB; Cowan C; Fizgerald K; Rader D; Kathiresan S
Atherosclerosis; 2018 Jan; 268():196-206. PubMed ID: 29183623
[TBL] [Abstract][Full Text] [Related]
20. Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors.
Tomlinson B; Wu QY; Zhong YM; Li YH
J Lipid Atheroscler; 2024 Jan; 13(1):2-20. PubMed ID: 38299167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
